Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) has successfully exported its natural psilocybin extract to New Zealand for a groundbreaking clinical trial addressing methamphetamine addiction. The study, conducted at Rangiwaho Marae in collaboration with Tū Wairua and the Mātai Medical Research Institute, marks the first integration of indigenous Māori knowledge systems with modern clinical methodologies in psychedelic therapy.
The first participants have completed preparatory sessions and received psilocybin-assisted therapy in a culturally-grounded setting. The initiative brings together indigenous leaders, health researchers, and industry partners, including Rua Bioscience and the Institute of Environmental Science and Research. The trial emphasizes cultural protocols and collective reflection to ensure participant safety and community well-being.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) ha esportato con successo il suo estratto naturale di psilocibina in Nuova Zelanda per un rivoluzionario studio clinico che affronta la dipendenza da metanfetamine. Lo studio, condotto presso il Rangiwaho Marae in collaborazione con Tū Wairua e il Mātai Medical Research Institute, segna la prima integrazione dei sistemi conoscitivi indigeni Māori con le metodologie cliniche moderne nella terapia psichedelica.
I primi partecipanti hanno completato le sessioni preparatorie e ricevuto terapia assistita da psilocibina in un contesto culturalmente radicato. L'iniziativa riunisce leader indigeni, ricercatori nel campo della salute e partner industriali, inclusi Rua Bioscience e l'Istituto di Scienza Ambientale e Ricerca. Il trial enfatizza i protocolli culturali e la riflessione collettiva per garantire la sicurezza dei partecipanti e il benessere della comunità.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) ha exportado con éxito su extracto natural de psilocibina a Nueva Zelanda para un innovador ensayo clínico que aborda la adicción a la metanfetamina. El estudio, realizado en el Rangiwaho Marae en colaboración con Tū Wairua y el Instituto de Investigación Médica Mātai, marca la primera integración de los sistemas de conocimiento indígenas Māori con las metodologías clínicas modernas en la terapia psicodélica.
Los primeros participantes han completado las sesiones preparatorias y han recibido terapia asistida con psilocibina en un entorno culturalmente arraigado. La iniciativa reúne a líderes indígenas, investigadores en salud y socios de la industria, entre ellos Rua Bioscience y el Instituto de Ciencia del Medio Ambiente e Investigación. El ensayo enfatiza los protocolos culturales y la reflexión colectiva para garantizar la seguridad de los participantes y el bienestar de la comunidad.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF)가 자연 산사포닌 추출물을 뉴질랜드로 성공적으로 수출하여 메탐페타민 중독을 다루는 획기적인 임상 시험을 진행했습니다. 이 연구는 Tū Wairua 및 Mātai Medical Research Institute와 협력하여 Rangiwaho Marae에서 수행되었으며, 이는 현대 임상 방법론과 원주민 마오리 지식 체계의 첫 통합을 나타냅니다.
첫 번째 참가자들은 준비 회의를 완료하고 문화적으로 기반한 환경에서 산사포닌 지원 치료를 받았습니다. 이 이니셔티브는 원주민 리더, 건강 연구자 및 산업 파트너(예: Rua Bioscience 및 환경과학 연구소)를 모읍니다. 이 시험은 참가자의 안전과 지역 사회의 복지를 보장하기 위해 문화적 프로토콜과 집단적 반성을 강조합니다.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) a réussi à exporter son extrait naturel de psilocybine en Nouvelle-Zélande pour un essai clinique révolutionnaire sur l'addiction aux méthamphétamines. L'étude, réalisée au Rangiwaho Marae en collaboration avec Tū Wairua et l'Institut de Recherche Médicale Mātai, représente la première intégration des systèmes de connaissance Māori indigènes avec les méthodologies cliniques modernes dans la thérapie psychédélique.
Les premiers participants ont complété des sessions préparatoires et ont reçu une thérapie assistée par la psilocybine dans un cadre culturellement ancré. L'initiative réunit des leaders indigènes, des chercheurs en santé et des partenaires industriels, y compris Rua Bioscience et l'Institut des Sciences de l'Environnement et de la Recherche. L'essai souligne les protocoles culturels et la réflexion collective pour garantir la sécurité des participants et le bien-être de la communauté.
Optimi Health Corp (CSE: OPTI) (OTCQX: OPTHF) hat erfolgreich seinen natürlichen Psilocybin-Extrakt nach Neuseeland exportiert, um eine wegweisende klinische Studie zur Behandlung der Methamphetaminabhängigkeit durchzuführen. Die Studie, die in Zusammenarbeit mit Tū Wairua und dem Mātai Medical Research Institute im Rangiwaho Marae durchgeführt wird, markiert die erste Integration der indigenen Māori-Wissen mit modernen klinischen Methoden in der psychedelischen Therapie.
Die ersten Teilnehmer haben vorbereitende Sitzungen abgeschlossen und in einem kulturell fundierten Umfeld Psilocybin-unterstützte Therapie erhalten. Die Initiative vereint indigene Führungspersönlichkeiten, Gesundheitsforscher und Industriepartner, darunter Rua Bioscience und das Institut für Umweltwissenschaften und Forschung. Die Studie legt besonderen Wert auf kulturelle Protokolle und kollektive Reflexion, um die Sicherheit der Teilnehmer und das Wohlergehen der Gemeinschaft zu gewährleisten.
- First successful export and administration of company's natural psilocybin extract in New Zealand clinical trial
- Strategic partnership with established research institutions and indigenous organizations
- Expansion into international markets through research collaborations
- None.
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks.
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, is proud to announce that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by Tū Wairua, and the Mātai Medical Research Institute, based in Gisborne, New Zealand.
The study is the first of its kind, combining indigenous Māori knowledge systems (mātauranga Māori) with cutting-edge clinical methodologies to address methamphetamine addiction. The inaugural cohort of participants has completed preparatory sessions and received psilocybin-assisted therapy in a culturally grounded, marae-based setting using Optimi's natural psilocybin extract.
Key Highlights
- First Participants Dosed: Optimi's natural psilocybin extract was administered to participants at Rangiwaho Marae, marking a historic step in combining traditional healing frameworks with modern therapeutic approaches.
- Innovative Collaboration: The Tū Wairua initiative unites indigenous leaders, health researchers, and industry partners, including Rua Bioscience (NZX:RUA) and the Institute of Environmental Science and Research (ESR), to explore the therapeutic potential of taonga (mushroom) varieties.
- Cultural Integration: The trial emphasizes tikanga (cultural protocols) and collective reflection to ensure the safety, feasibility, and long-term well-being of participants and their communities.
Supporting Indigenous Leadership in Psychedelic Therapies
"This is an incredible moment for Optimi and for the field of psychedelic medicine," said Dane Stevens, CEO of Optimi. "We are deeply honored to see our natural psilocybin extract being utilized in such a meaningful and culturally significant study. The Tū Wairua initiative is a testament to how modern science and indigenous knowledge can come together to address some of the world's most pressing mental health challenges. We look forward to continuing our support for groundbreaking programs like this, which have the potential to transform lives and inspire global change."
Dr. Patrick McHugh, lead investigator for the study and researcher at Mātai Medical Research Institute, stated, "The successful dosing of our first participants marks an important milestone in our work to address methamphetamine addiction through culturally grounded interventions. By integrating mātauranga Māori and tikanga into the clinical framework, we're not only exploring the therapeutic potential of psilocybin but also honoring the mana and well-being of the participants and their communities."
Building a Framework for Global Psychedelic Innovation
The study, supported by Rua Bioscience and other New Zealand-based organizations, is a testament to the global collaboration required to advance psychedelic medicine responsibly. Optimi's involvement underscores the Company's mission to make high-quality, natural psilocybin accessible to researchers and patients worldwide.
Learnings from this clinical trial will inform future trial phases and contribute to the broader understanding of psilocybin-assisted therapies.
Optimi invites research groups interested in utilizing its GMP-certified psilocybin to contact sales@optimihealth.ca for access to the investigator's brochure and pricing details.
About Optimi Health Corp.
Optimi Health Corp. is a Health Canada-licensed, GMP-compliant manufacturer and supplier of natural psilocybin and MDMA. Dedicated to producing high-quality psychedelic products, the Company aims to support the global advancement of mental health therapies through rigorous compliance, innovation, and collaboration.
On Behalf of the Board
JJ Wilson, Chair of the Board
For more information, please contact:
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including statements pertaining to the study, the results of such study, the benefits of using psilocybin and the potential for follow on studies. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's long form prospectus dated February 12, 2021, a copy of which is available on SEDAR+ at www.sedarplus.ca. Except as expressly required by applicable law, Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236949
FAQ
What is the purpose of Optimi Health's (OPTHF) psilocybin trial in New Zealand?
Where is OPTHF's psilocybin clinical trial being conducted in New Zealand?
What makes OPTHF's New Zealand psilocybin trial unique?
Who are the key partners in OPTHF's New Zealand psilocybin study?
